HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $32 to $45.